Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex 2-73 safety.

For those unfamiliar with the human clinical data showing profound safety of blarcamesine (Anavex 2-73), here, in the patent application, is a summary of the safety data from Phase 1 human trials:

Based on the frequency and intensity of non-treatment emergent adverse events (TEAEs) the maximum tolerable dose (MTD) and the minimum intolerable dose (MID) were defined as 55 mg and 60 mg, respectively. A highest doses, observed adverse events included moderate and reversible dizziness and headache, common in drugs that target the central nervous system. Blood pressure and resting heart rate and other clinical parameters such as vital signs and 12-lead electrocardiogram (ECG) did not show any clinically relevant or dose-dependent changes. The QT interval and QTcB also did not reveal any clinically significant changes. The pharmacokinetics of ANAVEX2-73 was found to be suitable for daily oral dosing.

Simply, the stuff is profoundly safe, uncommon for drugs acting in the central nervous system.

“A[t] highest doses, observed adverse events included moderate and reversible dizziness and headache....”

No effects on the cardiovascular system.

Anybody want to risk those side effects when Grandmother starts getting treated for her developing Alzheimer’s with blarcamesine? Sign her up.